


MRC Translational Funding



Award Rates 2017/18:

- Overall 24/129 – 16%**
- MICA 7/20 – 35%

** Normalised for the two stage process

Future Opportunities:

- Translation Accelerators
- Target Validation
- AI for healthcare
- Advanced therapeutics
- Talent and capacity building

Regional spread of MRC translational funding

- MRC annual research budget:
 - 70% on underpinning science
 - 30% on translation
- DPFS, Confidence in Concept and Proximity to Discovery funding is distributed across the UK



Proximity to Discovery (P2D): Industry Engagement Fund

- Institutional award to support early interactions between industry and academia and people & knowledge exchange
- P2D was paused in 2018/19 for review: Streamline support and simplify landscape in early translation/commercialisation
- MRC remains committed in supporting cross-sector engagement
- The MRC recognises the success in P2D in enabling early cross-sector engagement and its complementarity to its sister scheme Confidence in Concept (CiC) which focuses on early project support
- For future funding rounds, CiC and P2D will be combined into a single scheme to enable seamless support across the early translational space


Impacts of P2D to date

- **£13.2 million** awarded since 2014
- **27** universities supported
- **506** activities supported
- **274** people exchange supported
 - **206** exchanges from Academia to Industry
 - **68** exchanges from Industry to Academia
- **95** workshops
- **101** showcase and networking events

MRC Translational Research (2008-2018) Evaluation report



technopolis_{group}



Source: MRC spin-out database, Companies House. The data excludes spin-outs established in 2018 as these were not yet captured in the monitoring information



Geographical reach across the UK

134 spin-out companies

62 arising from translational schemes (DPFS and CiC).
30 companies raised £1.1bn of external equity investment.

These companies are valued at £2.7bn

59% of spin-outs emerged outside of London, Oxford and Cambridge

41% of total equity investment in new entrants to the UK pharmaceutical, biotechnology and medical technology sectors in 2018

92%(117) of these companies remained active in 2018 with 92% incorporated in the UK

A Strengthened Translational Research Culture

The most important factors highlighted in the evaluation for enabling translational research were **skills, collaboration, the right mindset** (attitudes and culture), and **funding**

Key opinion leaders and researchers agreed that MRC funding schemes had:

- Helped **change the culture** of the academic research community, with more researchers engaged in translational research
- Led to increased understanding and collaboration between **academia and the private sector**
- Led to increased **translational research skills** within academia

Report published on 12 September 2019



The evaluation report is available on the MRC website, along with seven Annexes with supporting material including the literature review, bibliometrics, and summaries of interviews

<https://mrc.ukri.org/publications/browse/10-year-translational-research-evaluation-report-2019/>

Contacts

For more info on P2D/CiC:

Agnes.Leong@mrc.ukri.org

For general translational funding or DPFS queries:

DPFSandDCS@mrc.ukri.org